Abstract: In the setting of neoadjuvant therapy (NAT) for pancreatic ductual adenocarcinoma (PDAC), accurate measurement of tumor size, and consequently, staging based on AJCC eighth edition, is difficult. Attempts to address the limitations of tumor size in the NAT setting have included correlation of residual tumor percent with survival. However, only cases with complete pathologic response or minimal residual disease have shown better prognosis compared with all other groups. To date, no studies have simultaneously evaluated the prognostic value of tumor size and tumor regression in the setting of PDAC status post NAT (NAT-PDAC). Our aim was to study the prognostic value of residual tumor index (RTI), a metric combining residual tumor percent and tumor bed size as an interaction term (% residual tumor×tumor bed size [cm]). In a cohort of 105 cases of NAT-PDAC, we show that RTI supersedes the prognostic value of AJCC eighth edition T staging via multivariate cox regression. At a binary cutoff of 0.35 for RTI, the hazard ratio for recurrence-free survival is 3.26 (95% confidence interval, 1.51-7.04), P < 0.01. We further identified cutoffs of ≤ 0.2, 0.2 to 2 and > 2 that stratified our cases into 3 groups via RTI, which were statistically significant in Kaplan-Meier curve analysis of recurrence-free survival (P < 0.01) and overall survival (P < 0.01). RTI represents a novel metric for combining the prognostic value of tumor size and residual tumor in NAT-PDAC.
P
ancreatic ductal adenocarcinoma (PDAC) is an infiltrative tumor which is characterized by a prominent desmoplastic stroma. Infiltrative glands, tumor nests, or single tumor cells microscopically often extend beyond the grossly estimated margins. 1 As a result of frequent coexistence of chronic pancreatitis in most patients, 2 and the similarity of tumor desmoplasia and benign fibrosis, gross assessment of tumor size is challenging and error-prone. Neoadjuvant therapy (NAT) generates local inflammation which results in profound fibrosis in both tumor and surrounding stroma. 3 Consequently, measuring the tumor/ tumor bed size is even more challenging, and sometimes impossible in NAT-treated PDAC cases (NAT-PDAC). The current AJCC tumor (T) staging system (eighth edition) is entirely based on tumor size, and therefore is difficult to apply in the setting of NAT. The largest multicenter validation study of the AJCC eighth edition staging system excluded NAT cases, 4 which leaves practicing pathologists with a lack of guidance in the staging of NAT-treated cases. Our previous preliminary work suggests that tumor categories of the new AJCC staging do not correlate well with overall survival (OS) in NAT-PDAC patients. 5 Therefore, new approaches for more effective quantification of tumor burden after NAT are needed.
Several studies have shown that tumor down-staging can be achieved following NAT, with a significant improvement in survival if tumors are subsequently resected. 6 Response to NAT is variable, but approximately one third of patients show benefit from NAT. Regardless of the pathologic treatment response to NAT, a fibrotic tumor bed can usually be identified, which becomes the gross measured tumor size for this group of resected tumors. There is no standardized method to define the tumor size in NAT-PDAC. It is at the discretion of the reporting pathologist to use either the gross tumor bed size, or the microscopically measured tumor dimension(s) to report the T stage. A common practice is to include only the microscopic measurement in the event that there is a single focus of tumor remaining in the entire tumor bed (scenario 1). However, the gross tumor bed size may still be considered as the tumor size when there is more than one focus of viable tumor in the tumor bed identified microscopically (scenario 2). Although there is not much difference in the amount of tumor burden in these 2 scenarios, the sizing conundrum leads to drastic variations in the size-based T staging. This issue is schematically illustrated in Figure 1 .
As the current AJCC T staging is not ideal for NAT-PDAC resection specimens, other pathologic parameters should be evaluated to aid in the current staging difficulties. Assessing the amount of residual tumor has been well-studied in NAT-PDAC. While the estimated residual tumor after NAT correlates well with survival in rectal adenocarcinomas, 7 this is not the case with PDAC. 8, 9 Multiple grading schemes for grading residual tumor in NAT-PDAC have been devised, the most popular being those proposed by the College of American Pathologists (CAP) 10 and Evans et al. 11 Multiple studies have shown that there is only a prognostic difference in the relatively rare group of tumors with complete pathologic response and tumors with near-complete response (occasional microscopic foci of residual tumor), versus all other tumors with any higher tumor burden. 8, 9 Assessment of the percentage of residual tumor alone cannot stratify these patients well, and clearly, better strategies are needed. Therefore, to get a more comprehensive pathologic parameter over the percentage of residual tumor alone, or just the tumor bed size, we combined these pathologic factors into what we defined as a residual tumor index (RTI), which is the product of viable residual tumor percentage and the greatest dimension of the tumor bed (% residual tumor×tumor bed size [cm] ). The goal of our study is to test if RTI is a meaningful pathologic prognosticator that could be used as an adjunct to current T staging, in order to accurately predict the risk of recurrence and OS in NAT-PDAC patients.
MATERIALS AND METHODS

Patient Population
A retrospective cohort of 105 consecutive patients was identified from a prospectively maintained database, with a confirmed cytologic or histologic diagnosis of PDAC before NAT followed by definitive surgical resection. Approval from the Institutional Review Board was obtained before initiating the study. All patients had tumors located in the head of pancreas and underwent NAT followed by surgical resection at our institution, from December 1999 to July 2017. Cases with complete medical records, including availability of all archival hematoxylin and eosin (H&E) slides and clinical follow-up data, were included in the study.
Pathologic Parameters
The H&E slides for all cases were reviewed to assess the percentage of residual tumor, compared with surrounding fibrosis in the tumor bed. To assess reproducibility in estimating the percentage of residual tumor, and therefore in calculating the RTI, the entire review was conducted separately by 2 pathologists, blindfolded to each other's assessment (D.C. and I.G.). There was an initial training session by the original reviewing pathologist (D.C.). Only H&E-stained slides were used for this purpose, and eyeball estimation was used. The final percentage of residual tumor assigned on a particular case was an estimated mean value after looking at all slides which contained tumor (Fig. 2) . The tumor bed in NAT-PDAC includes areas of desmoplasia extending even into and between the normal components of the parenchyma, making it challenging to digitally measure the exclusive tumor component only. Moreover, akin to estimating macrovesicular steatosis in a liver biopsy, where a pathologist's eyeballing to assess the percentage of fat is a standard practice, and is known to be reproducible despite its semiquantitative nature, we chose this similar way to assess the percentage of residual tumor in NAT-PDAC. Other usual pathologic parameters, such as tumor differentiation, lymphovascular invasion, perineural invasion, margin status, and lymph node status, were also verified. A record of tumor size (tumor bed size) was noted from the pathology reports, and in ambiguous cases, verified by histologic review.
Statistical Analysis
The clinical characteristics were summarized using descriptive statistics. OS was defined as the period of time from the date of surgery to the date of death, expressed in years. Alive patients are censored at the last follow-up. Recurrence-free survival (RFS) was defined as the period of time from the date of surgery to the date of detection of recurrence, expressed in years. Patients without recurrence are censored at the last follow-up. Recurrence-free probabilities were calculated using Kaplan-Meier plots.
The intraclass correlation (between 2 pathologists' assessments) was computed using the SAS Macro %INTRACC. Patients were divided into 3 groups based on RTI and their RFS and OS were compared. Differences between index categories were determined by log-rank test. The macro % findcut was used to define the best cut point for RTI, and residual tumor percent by finding the largest difference of log-rank test statistic between subjects in 2 groups. 12 Cox proportional-hazards models were used to evaluate the relationship of the interested variables for OS and RFS analysis, respectively. The proportionality assumption was tested by adding a time-dependent covariate for each variable. The variables with P < 0.20 from univariate models are considered in the multivariable model. The final multivariable model was built using the backward stepwise selection approach to identify all significant risk factors. Factors significant at a 10% level were kept in the final model. All statistical tests were 2-sided using α = 0.05 level of significance. SAS Version 9.4 (Cary, NC) was used to perform all statistical analyses.
RESULTS
Patient and Tumor Characteristics
The mean age of the patients in the study cohort was 63.4 years ( ± 11.5), 54.3% were females, and the patient population was mostly whites (91.4%) ( Table 1) . A total of 44.8% of all tumors were classified as poorly differentiated on histology, 50.5% were moderately differentiated, and 2.8% were well-differentiated. Tumor was present at the resection margins in 20% of cases and 21.9% of cases had tumor within 1 mm of resection margin. Using AJCC eighth edition staging guidelines, 30.4% of the cases were classified as T1c, 61.9% were T2 and 6.7% were T3. In one case, no definitive mass was identified on gross pathologic examination. In all, 34.3% of patients were classified as having N1 disease, 21.9% as N2 and 43.8% were classified as N0. Lymphatic invasion was present in 45.7% of the tumors and perineural invasion was identified in 76.2% of the tumors. A total of 47.6% patients received neoadjuvant FOLFIRINOX, 26.6% patients received Gemcitabine plus Abraxane, 20.9% patients received Gemcitabine alone and 2.9% received other 5-FU based regimens. Neoadjuvant radiation therapy was performed in 96.2% patients. Standard Whipple procedure was performed in 68.6% patients, pylorus sparing Whipple in 24.7%, Whipple at splenic artery 13 in 4.8% and total pancreatectomy in 1.9% patients. Patient and tumor characteristics are summarized in Table 1 .
Correlation of Assessment of Residual Tumor Between Pathologists
The intraclass correlation, computed using the SAS Macro %INTRACC, included a dataset of 107 patients with 2 pathologists' readings. The intraclass correlation showed a Shrout-Fleiss reliability single score of 0.97, strongly supporting interobserver agreement.
Residual Tumor Index and Recurrence-free Survival
Patient variables including age, sex, race, and preoperative chemotherapy and pathologic variables including tumor grade, lymphatic invasion, perineural invasion, margin status, involvement of lymph nodes, residual tumor percent (binary cutoff at 10%), and T stage were tested on univariate analysis for association with RFS. On Cox univariate analysis, N stage (P = 0.01), number of lymph nodes involved (P = 0.01), and RTI (P < 0.01) were significantly associated with RFS. Age, sex, race, tumor grade, margin status, perineural invasion, and lymphatic invasion were not significantly associated with RFS. On multivariate analysis, only RTI was significantly associated with RFS (Table 2) . Interestingly, on a separate analysis, both components of RTI, that is residual tumor percent and tumor bed size were independently associated with OS (P-value 0.03 and <0.01, respectively). Patients were divided into 3 categories: low, mid, and high, based on the RTI cutoffs of 0.2 and 2.0. Patients with high RTI had shorter RFS (P-value < 0.01) and OS (P-value < 0.01) compared with patients with low or mid RTI (Figs. 3, 4) . To understand this better, we further categorized patients into 2 groups, high and low RTI, as described in statistical methods above. A threshold of 0.35 for RTI was identified and patients were divided into 2 groups. RTI > 0.35 was significantly associated with shorter RFS (Table 2 and 
Residual Tumor Index and Overall Survival
On univariate analysis, lymphatic invasion (Pvalue =0.05), N stage (P-value < 0.01), number of lymph nodes involved (P < 0.01), T stage (P-value = 0.04), and RTI (P-value < 0.01) were significant predictors of OS post resection (Table 3) . However, on multivariate analysis RTI > 0.35 (hazard ratio = 2.40; 95% CI, 1.01-5.66; P-value = 0.05) and N stage (P-value = 0.04) were the only independent predictors of OS. This suggests that an RTI of 0.35 or higher is independently associated with poor OS (Table 3 ). The median OS in the RTI > 0.35 group was 1.82 years (95% CI, 1.52-2.15) which was significantly different from RTI < 0.35 group (median survival not achieved, P-value < 0.01, Fig. 6 ).
DISCUSSION
Evaluation of Residual PDAC After NAT
The assessment of residual tumor following NAT is addressed by a growing body of literature. Multiple groups, including CAP, have proposed grading systems with varying quantitative or qualitative cutoffs of residual tumor percent. 10, 11, 14, 15 Of these, White et al 15 demonstrated a survival difference based on residual tumor percent, but this was a single center study with 54 patients. Evaluation of the Evans and CAP residual tumor grading systems in 223 NAT-PDAC patients showed that a binary classification of patients with pathologic complete response and minimal residual tumor (Evans grades IV and III/CAP grades 0 and 1) had better survival rates than those with moderate and poor response (Evans grades IIb, IIa, and FIGURE 3. Kaplan-Meier survival curves of patients who underwent neoadjuvant therapy followed by surgical resection for PDAC categorized into 3 RTI groups ( ≤ 0.2, 0.2 to 2 and > 2). There is a significant difference in recurrence-free survival for patients with low RTI compared with high RTI (P < 0.01).
FIGURE 4. Kaplan-Meier survival curves of patients who underwent neoadjuvant therapy followed by surgical resection for PDAC categorized into 3 RTI groups ( ≤ 0.2, 0.2 to 2 and > 2). There is a significant difference in overall survival for patients with low RTI compared with high RTI (P < 0.01).
FIGURE 5. Kaplan-Meier survival curves of patients who underwent neoadjuvant therapy followed by surgical resection for PDAC categorized based on 2 statistically derived RTI groups. There is a significant difference in recurrence-free survival for patients with low RTI compared with high RTI (P < 0.01).
I/CAP grades 2 and 3). 8 In the current study, univariate cox regression model shows that residual tumor correlates with overall and RFS at a cutoff of 10%, which recapitulates the binary classification of our previous study. 8 In addition, this result supports the findings of White and colleagues that residual tumor percent correlates with OS. However, none of the residual tumor grading systems incorporate tumor bed size.
AJCC Eighth Edition T Stage Validity in Pancreatic Ductal Adenocarcinoma Status Post Neoadjuvant Therapy
The change in T staging of PDAC in the AJCC eighth edition suggests that tumor size alone supersedes the sometimes subjective evaluation of extrapancreatic extension, a criterion that was used in the previous T staging (AJCC seventh edition). A multi-institutional validation study by Allen et al 4 supporting this change shows that tumor size alone correlates with survival in patients undergoing surgical resection of PDAC. However, this study excluded patients who received NAT. Another recent validation study that used the Surveillance, Epidemiology and End Results (SEER) data set showed that the AJCC eighth edition staging was comparable to the AJCC seventh edition staging in NAT-PDAC cases. 16 Our results show that tumor bed size (as a continuous variable), and also AJCC eighth edition T stage correlate with survival in univariate cox regression, which offers additional support to the validity of the use of the AJCC eighth edition T stage in NAT-PDAC. 5 
Why Use RTI?
If residual tumor percent and AJCC eighth edition T stage both correlate with survival in NAT-PDAC, both parameters could be used separately for prognostication. However, these findings are difficult to combine into a discrete adjunctive tumor classification system for prognostication. Even if tumor bed size is reduced to a 4-tier system, and residual tumor is grouped in 4 categories as in the CAP system, the result would be 16 possible combinations of T stage and residual tumor percent. One possible solution is the use the product of tumor bed size and residual tumor percent, defined here as RTI. The RTI represents an efficient and simple means to combine the prognostic information contained in tumor bed size and tumor regression simultaneously. In this limited dataset, on multivariate analysis, RTI is superior to the predictive value of the AJCC eighth edition T stage, which is no longer significantly correlated with survival when RTI is included in the model.
The lack of simultaneous comparison of tumor bed size and residual tumor percent in previous studies has several major limitations. For example, in a system that only compares residual tumor percent, a 5.0 cm tumor bed with 20% residual tumor would be regarded as the same as a 0.5 cm tumor with 20% residual tumor, whereas the RTI would be 1.0 in the former and 0.1 in the latter-a difference of an order of magnitude. Table 4 displays the RTI over a range of tumor bed sizes and residual tumor percent. The RTI has as its maximum value the gross tumor bed size. In cases where there is no treatment response, the RTI is equal to the tumor bed size. Regardless of tumor bed size, the RTI is 0 if there is no residual tumor, and this result is consistent with the fact FIGURE 6. Kaplan-Meier survival curves of patients who underwent neoadjuvant therapy followed by surgical resection for PDAC categorized based on 2 statistically derived RTI groups. There is a significant difference in overall survival for patients with low RTI compared with high RTI (P < 0.01). Our survival data relative to the RTI should be interpreted in the context that NAT in PDAC has been associated with an improved rate of R0 resections which offers improved long-term survival. 17 Moreover, only selected patients who tolerate chemotherapy undergo the highly morbid abdominal surgery, which is associated with better postoperative outcomes. 18, 19 In this study we have selected NAT-treated patients who underwent surgical resection, therefore the overall prognosis of this cohort is expected to be better than stage-matched treatment-naive patients undergoing surgical resection for PDAC.
Limitations of Our Study
Estimating RTI involves subjective assessment of the percentage of residual tumor. Although it would have been ideal to find a way to quantitate this parameter objectively, there are practical limitations. PDAC are very infiltrative tumors, and are also associated with a lot of desmoplasia. For a resection specimen, the tumor is often sampled with the adjacent parenchyma to show the relationship to margins, which is an important prognostic pathologic parameter. Therefore, in these tumor sections, which are multiple (often > 10) per case, the tumor bed includes areas of desmoplasia extending even into and between the normal components of the parenchyma, making it challenging to quantitatively measure the exclusive tumor component only.
As calculating the RTI involves estimation of the percentage of residual tumor by eyeballing, the question of interobserver variability always remains. To address this issue, 2 pathologists were involved in our study, and assessments were carried out independently and blindfolded to each other's results. Subsequently, the intraclass correlation was computed using the SAS Macro %IN-TRACC. In accordance with previously accepted criteria by Landis and Koch, k values > 0.4 indicate "moderate agreement," values > 0.6 indicate "substantial agreement" and values > 0.8 indicate "excellent" or "near perfect agreement." 12 The intraclass correlation between 2 pathologists' readings in our study showed a Shrout-Fleiss reliability single score of 0.97, strongly supporting interobserver agreement in assessing RTI.
Another potential shortcoming of our study is that it is not adequately powered for subset analysis including comparing outcomes of patients with similar RTI but different tumor bed size or tumor response to NAT, for example, a nonresponsive 2 cm tumor (RTI = 2) versus a 4 cm tumor with 50% regression (RTI = 0.5×4 = 2). This is a conceptual study and it needs to be validated in a large multi-institutional cohort of patients with long-term recurrence and follow-up data.
CONCLUSIONS
The RTI simplifies the relationship between tumor bed size and residual tumor percent in NAT-PDAC cases, and supersedes the predictive value of AJCC eighth edition T stage in multivariate analysis. With our study also demonstrating interobserver reproducibility, assessment of RTI appears to be a practical method that can be used widely by pathologists in any practice setting. It does not require any special technique such as digital analysis, and does not consume more time than ordinarily taken to assess the other pathologic parameters for standardized reporting of such a specimen. Future studies and larger data sets are needed to validate the prognostic value of RTI, and may refine the subcategories beyond the cutoffs we defined with our dataset. 
